Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren vs Ramipril GI Safety in Hypertension
NCT00631917Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in essential hypertension (2 arms), sponsored by Novartis. Primary endpoints: Percentage of Participants With Colonic Pathology at 54 weeks and Summary of the End of Study Colonoscopy Results at 54 weeks. Started Feb 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00631917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00631917.